We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Blood Pressure Management Guidelines to Be Loosened

By HospiMedica International staff writers
Posted on 31 Dec 2013
The update to the guidelines for the management of hypertension raises the blood pressure threshold that determines the need for drug therapy in many patients.

The recommendations by the expert panel appointed to the Eighth Joint National Committee (JNC 8) suggest that for most hypertensive individuals 60 years of age or older, pharmacologic treatment should be started when the systolic pressure is 150 mm Hg or higher or diastolic pressure is 90 mm Hg or higher, with the goal of achieving readings below those cutoffs. More...
For younger hypertensive patients and for those with chronic kidney disease or diabetes (regardless of age) treatment should be initiated when the systolic pressure is 140 or higher or the diastolic pressure is 90 or higher.

To develop the recommendations, the panelists reviewed evidence from randomized, controlled trials only, unlike JNC 7, which included multiple types of studies. The guideline was focused on three specific questions; the blood pressure thresholds used to initiate treatment, blood pressure goals, and appropriate drugs. For the initial choice of agent, the authors recommended that for nonblack individuals, including those with diabetes, ACE inhibitors, angiotensin receptor blockers (ARBs), calcium channel blockers, and thiazide-type diuretics could all be chosen for first-line treatment.

For black individuals, including those with diabetes, calcium channel blockers and thiazide-type diuretics are recommended as first-line therapy. For patients with chronic kidney disease, regardless of race or diabetes status, initial or add-on therapy should include an ACE inhibitor or an ARB to improve renal outcomes. To provide some guidance on how clinicians should combine and adjust doses of various drugs, the panelists included a treatment algorithm, while stressing the importance of clinical judgment. The guideline was published online on December 18, 2013, in the Journal of the American Medical Association (JAMA).

“Although this guideline provides evidence-based recommendations for the management of high blood pressure and should meet the clinical needs of most patients, these recommendations are not a substitute for clinical judgment, and decisions about care must carefully consider and incorporate the clinical characteristics and circumstances of each individual patient,” stated panel co-chairs Paul James, MD, of the University of Iowa (Iowa City, USA) and Suzanne Oparil, MD, of the University of Alabama (Birmingham, USA), and colleagues.

The current guidance had a narrow focus and did not cover several subjects included in the JNC 7 recommendations, such as definitions of pre-hypertension and hypertension, measurement of blood pressure, patient evaluation, secondary hypertension, adherence to treatment regimens, resistant hypertension, and lifestyle interventions.

Related Links:

Eighth Joint National Committee



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Electric Bed
DIXION Intensive Care Bed
Hemostatic Agent
HEMOBLAST Bellows
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.